120 related articles for article (PubMed ID: 38452945)
1. The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells.
Lin IL; Lin YT; Chang YC; Kondapuram SK; Lin KH; Chen PC; Kuo CY; Coumar MS; Cheung CHA
Toxicol Appl Pharmacol; 2024 Apr; 485():116888. PubMed ID: 38452945
[TBL] [Abstract][Full Text] [Related]
2. The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells.
Chang YC; Kondapuram SK; Yang TH; Syed SB; Cheng SM; Lin TY; Lin YC; Coumar MS; Chang JY; Leung E; Cheung CHA
Toxicol Appl Pharmacol; 2020 Aug; 401():115080. PubMed ID: 32497533
[TBL] [Abstract][Full Text] [Related]
3. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
5. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
6. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
[TBL] [Abstract][Full Text] [Related]
7. Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.
Liao D; Zhang W; Gupta P; Lei ZN; Wang JQ; Cai CY; Vera AA; Zhang L; Chen ZS; Yang DH
Molecules; 2019 Nov; 24(23):. PubMed ID: 31801248
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
10. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
11. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Hsiao SH; Lusvarghi S; Huang YH; Ambudkar SV; Hsu SC; Wu CP
Cancer Lett; 2019 Mar; 445():34-44. PubMed ID: 30639533
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
Kikuchi H; Maishi N; Annan DA; Alam MT; Dawood RIH; Sato M; Morimoto M; Takeda R; Ishizuka K; Matsumoto R; Akino T; Tsuchiya K; Abe T; Osawa T; Miyajima N; Maruyama S; Harabayashi T; Azuma M; Yamashiro K; Ameda K; Kashiwagi A; Matsuno Y; Hida Y; Shinohara N; Hida K
Cancer Res; 2020 Jul; 80(14):2996-3008. PubMed ID: 32536602
[TBL] [Abstract][Full Text] [Related]
14. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates.
Gupta P; Gao HL; Ashar YV; Karadkhelkar NM; Yoganathan S; Chen ZS
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641875
[TBL] [Abstract][Full Text] [Related]
16. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
17. Novel Potent ABCB1 Modulator, Phenethylisoquinoline Alkaloid, Reverses Multidrug Resistance in Cancer Cell.
Sugisawa N; Ohnuma S; Ueda H; Murakami M; Sugiyama K; Ohsawa K; Kano K; Tokuyama H; Doi T; Aoki J; Ishida M; Kudoh K; Naitoh T; Ambudkar SV; Unno M
Mol Pharm; 2018 Sep; 15(9):4021-4030. PubMed ID: 30052463
[TBL] [Abstract][Full Text] [Related]
18. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.
Wang F; Li D; Zheng Z; Kin Wah To K; Chen Z; Zhong M; Su X; Chen L; Fu L
J Exp Clin Cancer Res; 2020 Mar; 39(1):50. PubMed ID: 32164732
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
[TBL] [Abstract][Full Text] [Related]
20. Interaction of SMAC with a survivin-derived peptide alters essential cancer hallmarks: Tumor growth, inflammation, and immunosuppression.
Santhanam M; Kumar Pandey S; Shteinfer-Kuzmine A; Paul A; Abusiam N; Zalk R; Shoshan-Barmatz V
Mol Ther; 2024 Jun; 32(6):1934-1955. PubMed ID: 38582961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
